Orexigen Therapeutics, Inc.

  • Will Orexigen's European Strategy Pay Off?

    By Spencer Osborne - August 20, 2013 | Tickers: ARNA, OREX, VVUS

    When people think of the anti-obesity space three companies typically come to mind.  Vivus (NASDAQ: VVUS), Arena Pharmaceuticals (NASDAQ: ARNA) and Orexigen Therapeutics (NASDAQ: OREX).  These three companies are at the new forefront of prescription anti-obesity medications.  The Vivus drug, Qsymia was the first to market last Fall.  Arena's Belviq this past June.  Meanwhile, Orexigen's Contrave is still in the midst of trials.  So why should the third more »

  • New Weight Loss Treatments Could Boost Sales for These 3 Biotechs

    By Leo Sun - August 13, 2013 | Tickers: ARNA, OREX, VVUS

    Arena Pharmaceuticals (NASDAQ: ARNA) is a controversial stock among biotech investors. The bulls believe that increasing rates of global obesity will inevitably trigger more sales of its new weight loss drug, Belviq, which was approved by the FDA last June. However, the bears believe that lingering safety concerns regarding Belviq and the company’s insistence on combining the treatment with other medications could cause problems down the road.

    Over the more »

  • How You Should Play These Weight-Loss Drug Companies

    By Sherrie Stone - July 22, 2013 | Tickers: ARNA, OREX, VVUS

    The two weight-loss drug approvals in 2012 were the first in more than a decade. The excitement surrounding Arena Pharmaceuticals(NASDAQ: ARNA) Belviq and Vivus’ (NASDAQ: VVUS) Qsymia led to massive gains in the months prior to their FDA approvals. Since then, both companies' shares have fallen as dramatically as they rose, suggesting a reoccurring pattern of high hopes and cruel reality for weight-loss drug makers. Will a third weight-loss more »

  • Qsymia Just Won The Lotto

    By Mohsin Saeed - June 27, 2013 | Tickers: ARNA, OREX, VVUS

    After almost a decade, the FDA has once again started approving obesity drugs. Vivus’ (NASDAQ: VVUS) Qysmia and Arena’s (NASDAQ: ARNA) Belviq have received FDA approval and are already available in the market. Belviq has just received DEA clearance and is a late entrant into the market, though the drug is regarded as the safer option and is readily available from local pharmacies. Orexigen’s (NASDAQ: OREX) Contrave is more »

  • Weight Loss Drug Sweepstakes

    By Alexander Maxwell - June 26, 2013 | Tickers: ARNA, OREX, VVUS

    The weight-loss industry has been heating up quite a bit over the past few quarters.

    First investors were reminded of the struggle between Vivus (NASDAQ: VVUS), Arena Pharmaceuticals (NASDAQ: ARNA) and Orexigen Therapeutics (NASDAQ: OREX) to see which company could get their drug on the market first. Now, that Vivus has Qsymia on the market and Arena has Belviq on the market, it appears as though all of the companies more »

  • 2 Biotech Approval Outcomes That Might Affect You

    By Sherrie Stone - June 19, 2013 | Tickers: ARNA, MNKD, OREX, VVUS

    An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-term gains. Thus, I am looking at two companies, both of which I expect to produce FDA approvals, but just one drug to create success in the open market.

    Possible approval, but not commercially successful

    MannKind Corporation (NASDAQ: MNKD) saw gains of more than 220% in 2013 more »

  • Why This Obesity Drug Is the Sector's Best Bet

    By Mohsin Saeed - May 24, 2013 | Tickers: ARNA, OREX, VVUS

    Editor's Note: The original article incorrectly stated Schedule IV drugs are the second-most-restrictive. This version has been corrected and Motley Fool apologizes for the oversight.

    The obesity drug space is becoming increasingly complex and hard to predict. After months of waiting patiently, Arena Pharmaceuticals (NASDAQ: ARNA) finally got a DEA schedule for its star drug Belviq in May, which could clear up the primary obstacle to Belviq’s availability more »

  • Will Obesity Drugs Gain Soon?

    By Brandy Betz - May 14, 2013 | Tickers: ARNA, NVO, OREX, VVUS

    Things are beginning to look slightly up for obesity drugmaker Vivus (NASDAQ: VVUS) -- mere weeks before a competing drug from Arena (NASDAQ: ARNA) hits the market.

    Vivus shares soared nearly 10% last Wednesday despite lackluster first quarter results. That’s because CEO Leland Wilson expressed an interest in finding a big pharma partner for the faltering Qsymia, which had a meager sales of $4.1 million in the quarter and more »

  • Looking at Arena Following Sell-Off

    By Chris Lau - May 13, 2013 | Tickers: ARNA, OREX, VVUS

    A sharp drop in Arena Pharmaceuticals (NASDAQ: ARNA) followed after the company reported quarterly earnings and a withdrawal of its Marketing Authorization Application (“MAA”) in the EU. Arena traded recently at around $8.00. Similar to Vivus (NASDAQ: VVUS), investor interest in the drug maker for obesity is unconvincing. Arena bounced back recently after the DEA approved the scheduling of Belviq. Now that "lorcaserin is subject to the CSA and more »

  • Improving Prospects of This Obesity Bet

    By Mohsin Saeed - May 6, 2013 | Tickers: ARNA, OREX, VVUS

    VIVUS' (NASDAQ: VVUS) Qsymia has not received the unconditional consumer love that investors were hoping. The initial sales data has been pretty slim, which has forced the company to lower prices more than once. VIVUS is trying to gain some sales momentum before its primary competitor, Belviq, from Arena Pharmaceuticals (NASDAQ: ARNA) hits stores.

    Orexigen Therapeutics (NASDAQ: OREX) is still trying to get the FDA to sign off on Contrave more »

  • Have Drugmakers Found the Panacea for Obesity? (Part I)

    By Shas Dey - April 29, 2013 | Tickers: ARNA, OREX, VVUS

    After a gap of several years, there seems to be a candidate in the obesity drug market that could turn out to be a long-term winner. Each drug in the market has its merits and demerits, but there is one with relatively strong market potential, in my opinion. It finally seems like obesity has become a surmountable challenge.

    The past record of obesity drugs has not been great. Going by more »

  • Exciting Catalysts Approaching for This Bet

    By Mohsin Saeed - April 27, 2013 | Tickers: ARNA, OREX, VVUS

    The obesity stocks are perhaps some of the most discussed and followed stocks in the entire biotechnology sector. The two drugs to receive FDA approval so far are Qsymia from VIVUS (NASDAQ: VVUS) and Belviq from Arena Pharmaceuticals (NASDAQ: ARNA). The third competitor, Orexigen (NASDAQ: OREX) is still trying to get the FDA to sign off on their obesity treatment Contrave. The drug is undergoing more tests to determine its more »

  • Anti-Obesity Stocks Are Attractively Priced

    By Ishtiaq Ahmed - April 23, 2013 | Tickers: ARNA, OREX, VVUS

    The obesity market was one of the most attractive sectors a year ago, and the shares of companies developing anti-obesity drugs were the pharmaceutical sector's hottest properties. However, it looks like investors hugely overvalued the market for anti-obesity drugs, resulting in tepid performance of these stocks.

    Only one company, Vivus (NASDAQ: VVUS) has been able to market its drug. However, Vivus’ drug, Qsymia, was approved with a long list more »

  • This anti-obesity drug will give you fat returns!

    By Manoj Kochar - April 18, 2013 | Tickers: ARNA, OREX, VVUS

    Obesity threatens the overall wellbeing of patients and is a major public health concern and the root cause of many of the world’s most widespread diseases including Type II diabetes and heart disease. 1/3 of American’s are facing obesity which prompted a controversial legal battle over the sale of sugary drinks in New York City. With a large part of the world fighting with obesity, a low more »

  • Which Obesity Drug Will Boost Your Portfolio?

    By Terry Chrisomalis - March 28, 2013 | Tickers: ARNA, OREX, VVUS

    In 2012, the FDA approved two obesity drugs for use in the United States. One drug, named "Belviq", is from Arena Pharmaceuticals (NASDAQ: ARNA) and the other, "Qsymia", is from VIVUS (NASDAQ: VVUS). There is another drug, named "Contrave", from a company known as  Orexigen Therapeutics (NASDAQ: OREX) but has not been approved yet by the FDA. 

    Arena's Belviq

    On June 27, U.S. regulators approved Belviq for use more »

  • Is the Wait Over?

    By Mohsin Saeed - March 7, 2013 | Tickers: ARNA, OREX, VVUS

    The obesity industry is new on the stock block, but it has already become one of the most followed industries in our market. The two major competitors Vivus (NASDAQ: VVUS) and Arena (NASDAQ: ARNA) have both received FDA approval for their drugs. Orexiegen (NASDAQ: OREX) is still trying to get approval for its obesity treatment Contrave. Vivus has already launched its obesity pill Qsymia into the US market. The launch more »

  • A Good Time to Make This Obesity Bet

    By Mohsin Saeed - March 4, 2013 | Tickers: ARNA, OREX, VVUS

    The obesity treatment market is a highly lucrative market due to the obesity epidemic hitting the States and the toll it is taking on medical insurance companies. Arena’s (NASDAQ: ARNA) Belviq and Vivus’s (NASDAQ: VVUS) Qsymia have already received FDA approval. Orexigen (NASDAQ: OREX) is testing their drug Contrave in a cardiovascular trial, and success in this trial can result in another obesity drug approval. Arena is holding more »

  • Which Is the Best "Obesity" Bet?

    By Mohsin Saeed - January 28, 2013 | Tickers: ARNA, OREX, VVUS

    The last year was an interesting one in the Biotechnology industry, with a number of different drugs receiving the FDA’s approval. In an unusual move, the body gave its nod to two drugs aiming to control the growing concern of obesity. As can be expected, after the approval of their respective drugs, the stock price of both Vivus (NASDAQ: VVUS) and Arena (NASDAQ: ARNA) skyrocketed. The analysts started churning more »

  • The Biggest Loser in the Obesity Drug Market

    By Adam Levy - January 17, 2013 | Tickers: AET, ARNA, OREX, VVUS

    Even while Americans have started focusing on eating healthy and exercising, obesity remains a problem that effects more than one in three adults in the United States. Diet and exercise are usually a good start in a quest to lose weight and get healthy, but sometimes “Biggest Loser” type efforts just aren’t possible or even enough to prevent heart disease, stroke, and diabetes.

    This is where prescription obesity drugs more »

  • Hedge Funds are Interested in Arena Pharmaceuticals

    By Michael Meyer - January 16, 2013 | Tickers: ARNA, OREX, VVUS

    One of the ways that retail investors can even out the flow of information is by following what hedge funds are investing in. A popular way to do this is to follow the 13F reports that hedge funds file each quarter. And while just blindly following what the big funds are buying is probably not the best idea, making this strategy one of your criteria for investing might be a more »

  • Page 1 of 3